Reposting w/additions.
This is the info I have compiled so far. I know there is more and most will have seen these but I thought it would be nice to have them all in one place.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/
https://twitter.com/ChasePlace532/status/1260556935469977601?s=20
https://docs.google.com/document/d/1545C_dJWMIAgqeLEsfo2U8Kq5WprDuARXrJl6N1aDjY/edit
https://twitter.com/Covid19Crusher/status/1256869896014704640?s=20
https://mobile.twitter.com/niro60487270/status/1260588201179144193
https://docs.google.com/document/d/1O6Cls-Oz2ZAgJuyDbnICEGjMvQPEyM-aaXARUomR9Ww/edit
https://eyewire.news/articles/aao-malaria-drugs-for-covid-19-will-not-blind-you/?utm_campaign=Enewsletters&utm_source=hs_email&utm_medium=email&utm_content=85914247&_hsenc=p2ANqtz-_HvOt8hUWuWhfTq_FfK6euHfcJaDKvwMb3Ug5wq57tdjYMr71t6pXk9fjEftw41vENIqAQljFl2hZdXqFc9BxvhfaQ&_hsmi=85914247
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Additions
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
1st link is press release. 2nd link is data. Scroll down to “Treatments”
https://app.sermo.com/covid19-barometer
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Comparison HCQ/Remesdivir
https://www.youtube.com/watch?v=iBma_0oAiMI&feature=youtu.be
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Pretty dense going for me. Maybe someone else can decipher.
https://threadreaderapp.com/thread/1259154540630364162.html
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
From Q
https://thetexan.news/pharmacy-board-loosens-restrictions-on-hydroxychloroquine-prescriptions-reversing-course/
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Excellent. Thanks
Pretty dense going for me. Maybe someone else can decipher.
https://threadreaderapp.com/thread/1259154540630364162.html
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
At baseline the HCQ pts were sicker...the patients from HCQ group were mostly already in a mild to moderate Acute Respiratory Distress Syndrome (ARDS) while the patients from the other group were not, as the PaO2/FiO2 shows. The HCQ patient group had more hypertension, were older, and male. However, they used stat adjustments to try to make the populations similar. “Despite this extensive adjustment, it is still possible that some amount of unmeasured confounding remains.”
Further, the authors used a composite endpoint, intubation (going on a vent) OR death. Just looking at Death as a Primary Outcome
HCQ: 157 / 262 = 60%
No-HCQ: 75/ 84 = 89% !
COVID patients who developed a respiratory failure in the NY hospital turned out to be 4 times more likely to survive when treated with HCQ. So why not use the hard endpoint Death? Why confabulate a composite?
Here’s my guess: all patients are driven by institutional ‘protocol’ or practice to be an intubated COVID-19 patient ($39000) vs just a COVID-19 patient ($13000). Thus, by adding the ‘OR intubation’ part to the composite endpoint the positive effect on death alone becomes diluted out.
AND/OR they wanted to show no HCQ effect.
Good ole NEJM. Always political.